Total
0
Shares
Visioneering Technologies (ASX:VTI) - CEO, Dr Stephen Snowdy - The Market Herald
CEO, Dr Stephen Snowdy
Source: The West Australian
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical device company Visioneering Technologies (VTI) has closed its security purchase plan after raising more than expected
  • While the company originally intended to raise $1 million, additional demand from eligible holders resulted in around $1.17 million in proceeds
  • The proceeds will be used for Visioneering’s international expansion, new product launches, clinical trials and other purposes
  • The company will issue new CHESS Depositary Interests and options from the SPP on April 14, 2021
  • Visioneering Technologies is in the grey and trading at 1.6 cents per share

Medical device company Visioneering Technologies (VTI) has closed its security purchase plan after raising more than expected.

Through the SPP, the company offered eligible security holders the chance to subscribe for up to A$30,000 in CHESS Depositary Interests (CDI’s). The CDI’s were offered at an issue price of 1.7 cents each, along with one free new listed option for every two new CDI’s subscribed for.

While Visioneering Technologies originally intended to raise only $1 million, additional demand from eligible security holders caused the SPP to become oversubscribed. In the end, the company increased the size of the security purchase plan and raised just over $1.17 million in proceeds.

This will result in the issue of 69,058,763 new CDI’s and 34,529,326 new options.

Visioneering Technologies’ CEO, Dr Stephen Snowdy, commented on the result of the company’s security purchase plan, and what the proceeds will fund.

“VTI is very pleased with the support we have received from our existing CDI holders under the SPP,” he said.

“The funds received under the SPP add to the $22.1 million raised under the placement in late March, and will be used for international expansion, new product launches, conduct of clinical trials, to meet general working capital purposes, and to fund VTI through to, or close to, break-even cash flow,” he added.

Visioneering Technologies will issue the new CDI’s and options to the eligible security holders on April 14, 2021. Holding statements will be dispatched the next day.

Visioneering Technologies is in the grey, trading at 1.6 cents per share at 1:11 pm AEST.

VTI by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" TGA fast tracks evaluation of Telix Pharmaceuticals’ (ASX:TLX) cancer imaging product

The Theraputic Goods Administration (TGA) has commenced a priority evaluation process for Telix Pharmaceuticals’ (TLX) prostate cancer imaging product, Illuccix.
Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left) - The Market Herald

" Pharmaxis (ASX:PXS) to raise $4.4M via placement

Pharmaxis (PXS) has received firm commitments to raise $4.4 million through a placement.
Universal Biosensors (ASX:UBI) - CEO, John Sharman - The Market Herald

" Universal Biosensors (ASX:UBI) toasts new distribution agreement for wine testing device

Universal Biosensors (UBI) has entered into a non-exclusive agreement with Singularity SpA to distribute its wine testing platform device in Chile.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" Paradigm Biopharmaceuticals (ASX:PAR) enrols first participant in osteoarthritis trial

Paradigm Biopharmaceuticals (PAR) has enrolled its first patient in its knee osteoarthritis (OA) biomarker study in Box Hill, Victoria.